Back to Journals » Patient Preference and Adherence » Volume 10

Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment

Authors Garcia-Dominguez JM, Muñoz D, Comellas M, Gozalbo I, Lizan L, Sánchez C, Martinez E

Received 8 June 2016

Accepted for publication 25 July 2016

Published 26 September 2016 Volume 2016:10 Pages 1945—1956

DOI https://doi.org/10.2147/PPA.S114619

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 3

Editor who approved publication: Dr Johnny Chen

José Manuel Garcia-Dominguez,1 Delicias Muñoz,2 Marta Comellas,3 Irmina Gonzalbo,3 Luis Lizán,3 Carlos Polanco Sánchez4

1Multiple Sclerosis Unit, Hospital General Universitario Gregorio Marañon, Madrid, 2Neurology Department, Hospital Universitario Alvaro Cunqueiro, Vigo, 3Outcomes’10, Jaime I University, Castellón, 4Health Economics & Outcomes Research, Merck, Madrid, Spain

Objectives: To assess disease-modifying therapy (DMT) preferences in a population of patients with multiple sclerosis (MS) and to estimate the association between sociodemographic and clinical factors and these preferences.
Methods: Preferences for DMTs attributes were measured using a discrete choice experiment. Analysis of preferences was assessed using mixed-logit hierarchical Bayes regression. A multilinear regression was used to evaluate the association between the preferences for each attribute and patients’ demographic and clinical characteristics. A Student’s t-test or Welch’s t-test was used for subgroup comparisons.
Results: A total of 125 patients were included in the final analysis (62.9% female, mean age 44.5 years, 71.5% with relapsing-remitting MS diagnosis). The most important factor for patients was the possibility of suffering from the side effects of the treatment (relative importance [RI] =50%), followed by a delay in disease progression (RI =19.4%), and route and frequency of administration (RI =14.3%). According to maximum acceptable risk, patients were willing to accept an increase of 3.8% in severity of side effects, for a delay of 1 year in disease progression. Treatment duration was the most prevalent factor affecting preferences, followed by the age of patients, type of MS, level of education, and the type of current treatment. Patients treated orally were significantly more concerned about the route and frequency of administration (P=0.026) than patients on injectable therapy. Naïve patients stated significantly less importance to prevention of relapses (P=0.021) and deterioration of the capacity for performing usual daily life activities (P=0.015). Finally, patients with >5 years since diagnosis were significantly less concerned about preventing disease progression (P=0.021), and more concerned about treatment side effects (P=0.052) than compared with patients with <5 years of MS history.
Conclusion:
The most important attribute for MS patients was side effects of DMTs, followed by delay in disability progression. Experience with DMTs and time since MS diagnosis changed patients’ preferences. These results give information to adjust new DMT treatment in order to satisfy patients’ preferences and therefore, improve adherence to treatment.

Keywords:
multiple sclerosis, preferences, conjoint analysis, discrete choice experiment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Medication adherence and persistence in type 2 diabetes mellitus: perspectives of patients, physicians and pharmacists on the Spanish health care system

Labrador Barba E, Rodríguez de Miguel M, Hernández-Mijares A, Alonso-Moreno FJ, Orera Peña ML, Aceituno S, Faus Dader MJ

Patient Preference and Adherence 2017, 11:707-718

Published Date: 4 April 2017

Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature

Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L

Patient Preference and Adherence 2016, 10:2357-2367

Published Date: 17 November 2016

Development and validation of a specific questionnaire to assess health-related quality of life in patients with home enteral nutrition: NutriQoL® development

Cuerda MC, Apezetxea A, Carrillo L, Casanueva F, Cuesta F, Irles JA, Virgili MN, Layola M, Lizan L

Patient Preference and Adherence 2016, 10:2289-2296

Published Date: 4 November 2016

Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain

Nolla JM, Rodríguez M, Martin-Mola E, Raya E, Ibero I, Nocea G, Aragon B, Lizán L, Prades M

Patient Preference and Adherence 2016, 10:1101-1113

Published Date: 20 June 2016

Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

Lizán L, Comellas M, Paz S, Poveda JL, Meletiche DM, Polanco C

Patient Preference and Adherence 2014, 8:1653-1664

Published Date: 4 December 2014